Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.
作者信息
Palladini Giovanni, Milani Paolo, Basset Marco, Russo Francesca, Lavatelli Francesca, Nuvolone Mario, Ferraro Giovanni, Bozzola Margherita, Foli Andrea, Perlini Stefano, Merlini Giampaolo
机构信息
a Amyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo , Pavia , Italy and.
b Department of Molecular Medicine , University of Pavia , Pavia , Italy.
出版信息
Amyloid. 2017 Mar;24(sup1):54-55. doi: 10.1080/13506129.2017.1289916.
Abstract
摘要
相似文献
1
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.
Amyloid. 2017 Mar;24(sup1):54-55. doi: 10.1080/13506129.2017.1289916.
2
Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.
Leukemia. 2019 Feb;33(2):527-531. doi: 10.1038/s41375-018-0258-y. Epub 2018 Sep 26.
3
Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis.
Amyloid. 2017 Mar;24(sup1):50-51. doi: 10.1080/13506129.2017.1286584.
4
Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.
Am J Hematol. 2021 Jan;96(1):E20-E23. doi: 10.1002/ajh.26025. Epub 2020 Nov 5.
5
Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type.
Amyloid. 2017 Mar;24(sup1):44-45. doi: 10.1080/13506129.2017.1281117.
6
Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement.
Hematol Oncol Clin North Am. 2020 Dec;34(6):1055-1068. doi: 10.1016/j.hoc.2020.07.006. Epub 2020 Sep 14.
7
Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Ann Hematol. 2018 Dec;97(12):2465-2470. doi: 10.1007/s00277-018-3460-0. Epub 2018 Jul 28.
8
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Amyloid. 2020 Mar;27(1):13-16. doi: 10.1080/13506129.2019.1666709. Epub 2019 Sep 23.
9
Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Circ J. 2019 Mar 25;83(4):775-782. doi: 10.1253/circj.CJ-18-1048. Epub 2019 Feb 16.
10
Revisiting complete response in light chain amyloidosis.
Leukemia. 2020 May;34(5):1472-1475. doi: 10.1038/s41375-019-0664-9. Epub 2019 Nov 26.
引用本文的文献
1
Role of the mechanisms for antibody repertoire diversification in monoclonal light chain deposition disorders: when a friend becomes foe.
Front Immunol. 2023 Jul 13;14:1203425. doi: 10.3389/fimmu.2023.1203425. eCollection 2023.
2
Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.
J Clin Med. 2020 Oct 9;9(10):3232. doi: 10.3390/jcm9103232.
Zotero 插件